Literature DB >> 27527087

In Vitro Activity of Isavuconazole against Rasamsonia Species.

J Steinmann1, S Dittmer2, J Houbraken3, J Buer2, P-M Rath2.   

Abstract

The in vitro susceptibilities to the novel triazole isavuconazole and six other antifungal agents of a large collection of Rasamsonia isolates (n = 47) belonging to seven species were determined. Isavuconazole and voriconazole had no in vitro activity (MIC, >32 mg/liter) against isolates of the Rasamsonia argillacea species complex. The echinocandins were the most potent antifungal drugs against all of the isolates tested (minimum effective concentration, ≤0.19 mg/liter).
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27527087      PMCID： PMC5075100          DOI： 10.1128/AAC.00742-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis.

Authors:  Marie Machouart; Dea Garcia-Hermoso; Alexandre Rivier; Noura Hassouni; Emilie Catherinot; Alexandra Salmon; Anne Debourgogne; Hélène Coignard; Marc Lecuit; Marie-Elisabeth Bougnoux; Stéphane Blanche; Olivier Lortholary
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents.

Authors:  M C Arendrup; J Meletiadis; J W Mouton; J Guinea; M Cuenca-Estrella; K Lagrou; S J Howard
Journal:  Clin Microbiol Infect       Date:  2016-02-03       Impact factor: 8.067

3.  Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD.

Authors:  T Valentin; P Neumeister; M Pichler; A Rohn; C Koidl; D Haas; B Heiling; M Asslaber; I Zollner-Schwetz; M Hoenigl; H J F Salzer; R Krause; W Buzina
Journal:  Bone Marrow Transplant       Date:  2011-07-25       Impact factor: 5.483

4.  Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.

Authors:  Dora E Corzo-León; Michael J Satlin; Rosemary Soave; Tsiporah B Shore; Audrey N Schuetz; Samantha E Jacobs; Thomas J Walsh
Journal:  Mycoses       Date:  2015-03-24       Impact factor: 4.377

5.  Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Pradeep Kumar Singh; Brijesh Sharma; Somayeh Dolatabadi; Ferry Hagen; Jacques F Meis
Journal:  Mycoses       Date:  2014-09-23       Impact factor: 4.377

6.  Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease.

Authors:  Suk See De Ravin; Malliswari Challipalli; Victoria Anderson; Yvonne R Shea; Beatriz Marciano; Dianne Hilligoss; Martha Marquesen; Rosamma Decastro; Yen-Chun Liu; Deanna A Sutton; Brian L Wickes; Patricia L Kammeyer; Lynne Sigler; Kathleen Sullivan; Elizabeth M Kang; Harry L Malech; Steven M Holland; Adrian M Zelazny
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

Review 7.  Rasamsonia argillacea species complex: taxonomy, pathogenesis and clinical relevance.

Authors:  Sandrine Giraud; Loïc Favennec; Marie-Elisabeth Bougnoux; Jean-Philippe Bouchara
Journal:  Future Microbiol       Date:  2013-08       Impact factor: 3.165

8.  Taxonomy and antifungal susceptibility of clinically important Rasamsonia species.

Authors:  J Houbraken; S Giraud; M Meijer; S Bertout; J C Frisvad; J F Meis; J P Bouchara; R A Samson
Journal:  J Clin Microbiol       Date:  2012-10-17       Impact factor: 5.948

9.  Validation of a novel real-time PCR for detecting Rasamsonia argillacea species complex in respiratory secretions from cystic fibrosis patients.

Authors:  J Steinmann; S Giraud; D Schmidt; L Sedlacek; A Hamprecht; J Houbraken; J F Meis; J P Bouchara; J Buer; P-M Rath
Journal:  New Microbes New Infect       Date:  2014-04-20

10.  Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Authors:  George R Thompson; Adrian Rendon; Rodrigo Ribeiro Dos Santos; Flavio Queiroz-Telles; Luis Ostrosky-Zeichner; Nkechi Azie; Rochelle Maher; Misun Lee; Laura Kovanda; Marc Engelhardt; Jose A Vazquez; Oliver A Cornely; John R Perfect
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079
View more
  4 in total

1.  Diagnosis from Tissue: Histology and Identification.

Authors:  Raquel Sabino; Nathan Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-05-13

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

Authors:  Matthew W McCarthy; Brad Moriyama; Ruta Petraitiene; Thomas J Walsh; Vidmantas Petraitis
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

3.  Systemic Rasamsonia piperina infection in a German shepherd cross dog.

Authors:  Joanna Lodzinska; Paola Cazzini; Claire S Taylor; Jenifer Harris; Scott Kilpatrick; Tiziana Liuti; Gavin K Paterson
Journal:  JMM Case Rep       Date:  2017-10-18

Review 4.  Emerging Fungal Infections: New Species, New Names, and Antifungal Resistance.

Authors:  Nathan P Wiederhold
Journal:  Clin Chem       Date:  2021-12-30       Impact factor: 12.167
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.